Premium
A Turkish Gynecologic Oncology Group study of fertility‐sparing treatment for early‐stage endometrial cancer
Author(s) -
Dursun Polat,
Erkanli Serkan,
Güzel Ahmet Bariş,
Gultekin Murat,
Tarhan Nefise Cagla,
Altundag Ozden,
Demirkiran Fuat,
Beşe Tugan,
Yildirim Yusuf,
Bozdag Gurkan,
Yarali Hakan,
Simsek Tayyup,
Ozcelik Bulent,
Ortaç Firat,
Taskin Salih,
Guvenal Tevfik,
Ozgul Nejat,
Haberal Ali,
Vardar M. Ali,
Dede Murat,
Yenen Mufit,
Altintas Aytekin,
Arvas Macit,
Ayhan Ali
Publication year - 2012
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2012.06.010
Subject(s) - medicine , pregnancy , endometrial cancer , stage (stratigraphy) , gynecologic oncology , fertility , turkish , fertility preservation , obstetrics , gynecology , cancer , population , paleontology , linguistics , philosophy , genetics , environmental health , biology
Objective To analyze the results of fertility‐sparing treatment of early‐stage endometrial cancer (EC) in patients treated at Turkish gynecologic oncology centers, and to present a review of the literature. Methods Thirteen healthcare centers in Turkey were contacted to determine if they were eligible to participate in the study. Centers that were eligible and agreed to participate were sent a database form to record the demographic characteristics, clinicopathologic findings, and follow‐up results for their EC patients. Results Eleven Turkish healthcare centers provided data on 43 EC patients. Mean duration of treatment was 5 months and mean follow‐up was 49 months. In total, 35 (81.4%) patients were tumor free following primary progesterone therapy. Mean time from the end of progesterone therapy to pregnancy was 10.6 ± 4.3 months (range, 3–18 months). Two patients had tumor recurrence during follow‐up. The pregnancy rate among the 31 women who actively sought pregnancy was 41.9% (n = 13). Conclusion Conservative management of early‐stage EC in women of reproductive age using oral progestins was effective and did not compromise oncological outcome. Pregnancy in the study patients was achieved spontaneously and artificially.